Contact
Please use this form to send email to PR contact of this press release:
Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop
TO: